Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia
Less than 40% of patients with newly diagnosed adult immune thrombocytopenia will show spontaneous recovery within 12 months. Therefore, second-line treatments are frequently used to maintain a hemostatic platelet count or at best to cure the disease, with as few adverse effects as possible. Neverth...
Na minha lista:
| Principais autores: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis Group
2020-04-01
|
| 叢編: | Platelets |
| 主題: | |
| 在線閱讀: | http://dx.doi.org/10.1080/09537104.2019.1636018 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|